CRISPR Cholesterol Therapy Cuts Bad Fat in Half for a Year

A single infusion of an experimental CRISPR cholesterol therapy kept LDL and triglycerides roughly half their starting levels a year later, in the first trial of the treatment in people. The therapy, called CTX310, was tested at Cleveland Clinic in fifteen people with medication-resistant lipid disorders, whose blood fats stayed high despite standard drugs. According to the clinic, the reductions persisted at every dose tested through the year of follow-up.

Patients in the highest dose group saw the largest effect. A year after the single treatment, LDL ("bad") cholesterol was 52.5 percent below its pre-treatment level, and triglycerides were 47.8 percent lower. Circulating levels of the targeted gene's protein product fell about 79 percent. During the year of follow-up, there were no serious adverse events related to the treatment.

The results were presented at the 2026 European Society of Cardiology annual meeting and published at the same time in the New England Journal of Medicine. They follow initial two-month findings reported in November 2025, which showed the treatment lowered blood fats quickly. The new data answer the question that followed: whether a one-time edit to a patient's DNA would keep working. It did.

How switching off one liver gene lowers blood fats

CTX310 uses CRISPR-Cas9, a technology that modifies specific regions of DNA, to switch off a gene called ANGPTL3 in the liver. The gene helps regulate blood fats, and disabling it lowers LDL cholesterol and triglycerides, two lipid measures closely tied to heart disease risk.

The therapy is given as a one-time infusion that carries the CRISPR editing machinery into liver cells. Because the edit alters the DNA of those cells, the effect is meant to be durable. That distinguishes it from daily pills and from newer injected cholesterol drugs, which have to be taken continuously to keep working. The field is moving fast: researchers recently found a virus enzyme that could aid gene editing, and cracked a 20-year puzzle in DNA repair.

The CRISPR cholesterol study used a standard dose-escalation design. Participants received doses from 0.1 to 0.8 milligrams per kilogram of body weight, after pretreatment with corticosteroids and antihistamines. Researchers started small to establish safety, then raised the dose to measure the effect. Blood fat reductions appeared at every dose level, with the strongest effect at the top.

Dr. Luke Laffin, a Cleveland Clinic cardiologist and the study's first author, called the durability of the effect "impressive." He said the absence of serious safety events related to CTX310 was "encouraging," and that the therapy needs testing in a larger number of patients, according to the clinic.

What the results mean

This was a Phase 1 trial, designed mainly to test safety, and it was small. The headline figures come from four people at the highest dose. The study measured cholesterol and triglyceride levels, not heart attacks or strokes, so whether editing this gene prevents cardiovascular events will take much larger and longer trials. That evidence does not exist yet.

CTX310 is investigational and unapproved, and the results do not change what anyone with high cholesterol should do now. Statins and other approved lipid-lowering drugs have large outcome trials behind them and remain the appropriate treatment for people who need cholesterol lowering today. A one-dose gene edit is not ready to replace them, and may never suit the broad population that takes statins.

The edit to liver cells is designed to be permanent, which is why participants will be monitored for another decade and a half. That is the standard long-term follow-up the US Food and Drug Administration requires for gene-editing therapies, reflecting both the promise and the caution around any treatment that permanently alters a person's genome.

The funding belongs in the picture. CRISPR Therapeutics, the company developing CTX310, funded the study, and the first author's institution has received research funding from the company. That relationship does not invalidate the findings, but it matters when weighing early results from a small, company-backed trial. The full results are published in the New England Journal of Medicine, where other scientists can examine the methods and data.

For now, CTX310 stands as a proof of concept with a year of data behind it: one infusion that switched off a single liver gene and kept blood fats near half their starting level. If larger trials confirm the effect and the safety, the CRISPR cholesterol approach could give people whose cholesterol resists today's medicines a very different option, with no daily pill to take. Read the Cleveland Clinic trial report and SciTechDaily's write-up for more detail.